MWNA
HARP

Marshall Wace North America’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Marshall Wace North America’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.8M Hold
22,813
– – 0.01% 754
2021
Q2 		$3.16M Buy
22,813
+548
+2% +$105K 0.01% 672
2021
Q1 		$4.66M Buy
22,265
+8,361
+60% +$1.68M 0.02% 587
2020
Q4 		$2.31M Buy
+13,904
New +$2.15M 0.01% 718

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace North America's HARP Position: Q3 2021 in Review

Marshall Wace North America held its Harpoon Therapeutics, Inc. Common Stock (HARP) position steady in Q3 2021 at 22,813 shares worth $1.8M. The position accounts for 0.01% of the portfolio, ranked #754.

Marshall Wace North America first reported a position in HARP in Q4 2020 and has held it in 4 quarters since. The position peaked at $4.66M in Q1 2021. 93 funds tracked by Wall St. Rank hold HARP as of Q3 2021.

  • Marshall Wace North America held 22,813 shares of Harpoon Therapeutics, Inc. Common Stock worth $1.8M as of Q3 2021.
  • Marshall Wace North America left its Harpoon Therapeutics, Inc. Common Stock share count unchanged in Q3 2021.
  • Harpoon Therapeutics, Inc. Common Stock made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #754 holding.
  • Marshall Wace North America first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2020 and has held it in 4 quarters since.
  • Marshall Wace North America's Harpoon Therapeutics, Inc. Common Stock position peaked at $4.66M in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.